Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Total Current Liabilities (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Total Current Liabilities for 4 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 21.21% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 21.21% increase, with the full-year FY2025 number at $4.2 million, changed N/A from a year prior.
  • Total Current Liabilities was $2.6 million for Q4 2025 at Neuphoria Therapeutics, down from $5.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $5.1 million in Q3 2025 to a low of $1.6 million in Q1 2025.
  • A 4-year average of $2.9 million and a median of $2.6 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: grew 14.83% in 2023, then surged 100.82% in 2025.
  • Neuphoria Therapeutics' Total Current Liabilities stood at $2.4 million in 2022, then increased by 14.83% to $2.8 million in 2023, then decreased by 22.69% to $2.1 million in 2024, then increased by 21.21% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Total Current Liabilities are $2.6 million (Q4 2025), $5.1 million (Q3 2025), and $4.2 million (Q2 2025).